HUM Court Ruling Analysis

Final — all horizons settled through T+60d ⚠ clustered

HUM ▲ +63.41% at T+60d

NEUTRAL call ✓ call won +63.41% · α vs SPY +54.09% · entry $187.00 → $305.57

Last close $379.22 (close Jun 12) · +102.80% from $187.00 entry

Entry anchored
Feb 27, 03:59 PM ET
via Databento tick

T+1d

-3.29%

call -3.29% · α -2.38%

$180.84

settled 4mo ago

T+5d

-4.96%

call -4.96% · α -3.76%

$177.72

settled 3mo ago

T+20d

-11.23%

call -11.23% · α -3.29%

$166.00

settled 3mo ago

T+60d

+63.41%

call +63.41% · α +54.09%

$305.57

settled 20d ago

Price Chart

Loading chart...

Executive Summary

In the Generic Pharmaceuticals MDL, Judge Rufe ruled on Epic Pharma's motions to dismiss antitrust claims regarding Ursodiol pricing. Humana's complaint was among eight that survived dismissal, as the court found sufficient allegations that Epic conspired with Lannett and Actavis to raise Ursodiol prices over 1000%. Three other complaints (HCSC, Molina, CVS) were dismissed against Epic for insufficient pleading. This is an interlocutory ruling—the case continues against Epic for Humana, with no damages awarded or financial exposure quantified.

Court Ruling Details

Ruling Date

Feb 27, 2026

Court

United States District Court for the Eastern District of Pennsylvania

Court Level

District

Judge

Cynthia M. Rufe

Case Type

antitrust

Ruling Type

motion to dismiss

Outcome

PARTIAL — mixed ruling, some claims won/lost

Will It Be Appealed?

Unlikely

Precedent Risk

LOW

Actionable Insight

Humana's antitrust claims against Epic survive dismissal, but this is an early-stage procedural ruling with no immediate financial impact. Monitor for summary judgment motions and potential settlement developments as discovery progresses. The MDL remains active, and any eventual recovery would likely be years away.

Key Facts

Humana Inc. is a plaintiff in the multidistrict antitrust litigation against generic drug manufacturers over price-fixing of Ursodiol.
The court denied Epic Pharma's motion to dismiss Humana's complaint, finding it sufficiently alleged Epic conspired to raise Ursodiol prices.
The ruling is interlocutory—no damages have been awarded; the case proceeds to discovery.
Three other complaints (HCSC, Molina, CVS) were dismissed against Epic for failure to state a claim.
No financial exposure or damages amount is stated in the opinion.

Financial Impact

No damages or financial exposure quantified in the ruling.

Risk Factors

No damages have been awarded; the case is in early discovery stage.
Epic may succeed on summary judgment or at trial.
Any potential recovery for Humana is uncertain and likely years away.

Market Snapshot

Exchange

NYSE

Sector

Hospital & Medical Service Plans

Analyst Consensus

33% bullish (33 analysts)

Documents Analyzed

This report is based on 1 court opinion from CourtListener.

Document	Accession Number
COURT-RULING Data (Synthetic)	court-1as9hv5f-HUM

5 reports for HUM

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for HUM — sortable, filterable
	Type				Now
Jun 1, 2026 13d ago	8-K NEUTRAL ★ 3/10	$328.31 $350.08	▲ +6.63%	▲ +9.38%	$379.22 (+15.51%)
Apr 10, 2026 9w ago	8-K NEUTRAL ★ 3/10	$197.53 $209.92	▲ +6.27%	▲ +2.98%	$379.22 (+91.98%)
Mar 6, 2026 14w ago	DEFA14A NEUTRAL ★ 3/10	$179.09 $165.30	▼ −7.70%	▼ −6.17%	$379.22 (+111.75%)
Mar 2, 2026 15w ago	Court Ruling NEUTRAL ★ 4/10	$187.00 $177.72	▼ −4.96%	▼ −3.76%	$379.22 (+102.80%)
Mar 2, 2026 15w ago	Court Ruling BULLISH ★ 5/10	$187.00 $177.72	▼ −4.96%	▼ −3.76%	$379.22 (+102.80%)

US Market Status

Market Closed — Opens in 3h 45m

Related Tickers

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access